Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $54.1600 (11.62%) ($54.1600 - $54.1600) on Fri. Feb. 5, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.34% (three month average) | RSI | 61 | Latest Price | $54.1600(11.62%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(63%) ARKK(59%) IBB(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.17% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-19%) UNG(-3%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.17% (StdDev 6.34%) | Hourly BBV | 2.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $49.74(8.89%) | 10 Day Moving Average | $49.22(10.04%) | 20 Day Moving Average | $50(8.32%) | To recent high | -1% | To recent low | 99.4% | Market Cap | $6.859b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |